Is Matinas BioPharma Holdings, Inc. (MTNB) a Buy, Sell, or Hold?
Matinas BioPharma Holdings, Inc.
AMEX:MTNB
$0.3498 USD
-$0.13 (-27.12%)
- Volume
- 4.13M
- Average Volume
- 183.82K
- Market Capitalization
- $1.94M
- P/E Ratio
- -0.17
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $3.09
- Year Low
- $0.31
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.32
Industry, Sector & symbol
| Stock Exchange | AMEX |
| CEO | Jerome D. Jabbour |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | MTNB |
| CUSIP | 576810303 |
| CIK | 0001582554 |
| Web | https://www.matinasbiopharma.com |
| Phone | 908 484 8805 |
| Currency | USD |
| Employees | 4 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.39 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.32 |
| Quick Ratio | 1.32 |
| Cash Ratio | 1.15 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.03 |
| Price / Cash Flow | -0.29 |
| Price / Book | 0.74 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2 |
| Trailing P/E Ratio | -0.17 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-10.34M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -204.27% |
| Return on Assets | -191.15% |
Financials Score
| AltmanZ Score | -55.99 |
| Piotroski Score | 1.00 |
| Working Capital | 689K |
| Total Assets | 5.87M |
| Ebit | -10.34M |
| Market Cap | 1.78M |
| Total Liabilities | 2.85M |
Poll Results
About Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Stock
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in ... Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.
2026-07-13 08:00:00
Will create publicly traded advanced clean energy company focused on modular carbon-free energy, green hydrogen, critical materials and industrial decarbonization
2026-06-26 17:15:00
BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders' equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders' equity of $3.02 million and has had losses in the most recent five fiscal years ended December 31, 2025. As previously disclosed, the Company is also not in compliance with Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders' equity of at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As of December 31, 2025, the Company had stockholders' equity of $4.83 million and has had losses in the most recent five fiscal years ended December 31, 2025. Due to its non-compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide, the Company is subject to the procedures and requirements of Section 1009 of the Company Guide.
2026-06-26 17:15:00
BEDMINSTER, N. J. , June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders' equity of at least $4.
Frequently Asked Questions
-
What is the current Matinas BioPharma Holdings, Inc. (MTNB) stock price?
-
Matinas BioPharma Holdings, Inc.(AMEX:MTNB) stock price is $0.3498 in the last trading session. During the trading session, MTNB stock reached the peak price of $3.09 while $0.31 was the lowest point it dropped to. The percentage change in MTNB stock occurred in the recent session was --27.12% while the dollar amount for the price change in MTNB stock was -$-0.13.
-
MTNB's industry and sector of operation?
-
The AMEX listed MTNB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MTNB?
-
Jerome D. Jabbour | Co-Founder, Chairman, CEO, President & Interim CFO
|
|
|
| -
How many employees does MTNB have?
-
Number of MTNB employees currently stands at 4. MTNB operates from 1545 Route 206 South, Bedminster, NJ 07921, US.
-
Link for MTNB official website?
-
Official Website of MTNB is: https://www.matinasbiopharma.com
-
How do I contact MTNB?
-
MTNB could be contacted at phone #908 484 8805 and can also be accessed through its website. MTNB operates from 1545 Route 206 South, Bedminster, NJ 07921, US.
-
How many shares of MTNB are traded daily?
-
The average number of MTNB shares traded daily for last 3 months was 183.82K.
-
What is the market cap of MTNB currently?
-
The market value of MTNB currently stands at $1.94M with its latest stock price at $0.3498